

Remarks

Amendments to the Claims

Claims 1-14, 18, 21-27, 31 and 34 have been canceled. Claims 35-36 have been added. Claims 15, 17, and 19 have been amended to recite the elements of claim 8, the claim from which they depend, now canceled. Claims 28, 30, and 32 have been amended to recite the elements of claim 21, the claim from which they depend, now canceled. None of these amendments narrow the scope of the claims.

New claim 35 is directed to isolated fusion proteins. The isolated fusion proteins comprise a portion of CFTR protein that consists of between 18 and 100 amino acid residues and comprises 18 contiguous amino acid residues as shown in SEQ ID NO:1. New claim 35 is supported by the specification which discloses at page 6, lines 18-19 that the “portion [of CFTR] preferably contains at least 18 amino acids as shown in SEQ ID NO:1” and at page 6, lines 22-23 which discloses that the “polypeptide may be from about 10 or 15 amino acid residues up to about 30 or even 100 amino acid residues.” New claim 35 also recites that the fusion protein does not comprise full-length CFTR. This recitation is supported by the specification which discloses, “Preferably the polypeptide will be free of full-length CFTR.” (Page 7, lines 2-3.)

Amendments to the Specification

The specification has been amended to update the priority data for the application.


The specification has also been amended to add sequence identifiers to describe the sequences disclosed in the drawings.

The specification has also been amended such that all hyperlinks are removed, and have been replaced with descriptions of the websites to which those hyperlinks refer.

No new matter is introduced by these amendments. Their entry is respectfully requested.

Respectfully submitted,

Date: December 23, 2003

By: 
Michelle L. Holmes-Son
Registration No. 47,660

Banner & Witcoff, Ltd.
1001 G Street, N.W., Eleventh Floor
Washington, D.C. 20001-4597
(202) 824-3000